Please use a PC Browser to access Register-Tadawul
Get It
Cardinal Health Provides Preliminary FY26 Guidance With Non-GAAP EPS Of $9.10-$9.30, Adj. FCF Of $2.75B-$3.25B, Capital Expenditures ~$600M, Sees Segment Revenue Growth Across Key Divisions; Updates Long-Term Targets Through 2028 Including 12% - 1...
Cardinal Health, Inc. -0.07% Pre
Cardinal Health, Inc. CAH | 198.18 198.18 | -0.07% 0.00% Pre |
Preliminary fiscal year 2026 guidance
The company is providing preliminary guidance for fiscal year 2026:
| Non-GAAP diluted EPS | $9.10 to $9.30 (+13% growth at mid-points) |
| Adjusted free cash flow | $2.75B to $3.25B |
| Capital expenditures | ~$600M |
| Interest and other | ~$275M |
| Non-GAAP effective tax rate | 22% to 24% |
| Pharmaceutical and Specialty Solutions: | |
| Revenue | 11% to 13% growth |
| Segment profit (Reported) | 10% to 12% growth |
| Segment profit (Normalized)4 | 5% to 7% growth |
| Global Medical Products and Distribution: | |
| Revenue | 3% to 5% growth |
| Segment profit | $140M+ |
| Other5: | |
| Revenue (Reported) | 26% to 28% growth |
| Segment profit (Reported) | 25% to 27% growth |
| Revenue (Normalized)4 | 10% to 12% growth |
| Segment profit (Normalized)4 | ~10% growth |
Long-term targets
The company is providing updated long-term targets (fiscal years 2026 to 2028 CAGRs3):
| Non-GAAP diluted EPS | 12% to 14% growth |
| Pharmaceutical and Specialty Solutions: | |
| Revenue | 8% to 10% growth |
| Segment profit (Reported) | 7% to 9% growth |
| Segment profit (Normalized)4 | 5% to 7% growth |
| Global Medical Products and Distribution: | |
| Revenue | 2% to 4% growth |
| Segment profit | $50M+ of profit growth per year after FY26 |
| Other5: | |
| Revenue (Reported) | 16% to 18% growth |
| Segment profit (Reported) | 15% to 17% growth |
| Revenue (Normalized)4 | 10% to 12% growth |
| Segment profit (Normalized)4 | ~10% growth |
| Adjusted Free Cash Flow (FY26 to FY28 total) | At least $10B |
| Share Repurchases (FY26 to FY28 total) | At least $2.25B |
